AstraZeneca Forms Joint Venture with Wuxi AppTec to Accelerate Biologics Development in China

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)

Published: 26 Sep-2012

DOI: 10.3833/pdr.v2012.i9.1805     ISSN: 1756-7874

Section: Joint Venture

Fulltext:

Abstract

AstraZeneca has formed a joint venture (JV) with Chinese CRO WuXi AppTec to accelerate the development and commercialisation of MEDI5117, an antibody therapeutic targeting interleukin-6 that is being developed for autoimmune and inflammatory diseases, in China...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details